Catarina Lopes Pereira

Views are my own

[Liese Barbier @LieseBarbier]

@drddawoud Best practices for tender organization include ensuring market plurality, including award criteria beyond price, fostering equal opportunity for suppliers, stimulating timely opening of tenders after biosimilar market entry,.. (2/2) #ISPORBiosimilars #procurement

[Liese Barbier @LieseBarbier]

@drddawoud When designed efficiently and conducted appropriately, tenders can stimulate (biosimilar) competition and as such form a cornerstone for sustainable market dynamics. (1/2) #ISPORBiosimilars #biosimilars #tender #procurement

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud Examples on positive initiatives on procurement that enable long term access to biosimilars, check out below
NHS England drafted in 2017 a document on procurement principles ‘Commissioning framework for biological medicines (including biosimilar medicines)‘ #ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud ...more initiatives... Italy Procurement law on biosimilar medicines )in force in 2016, check out more on page 9 of the report: KPMG (2019). Improving healthcare delivery in hospitals by optimized utilization of medicines #ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud Yes! after the entry of biosimilars, HTA bodies can update treatment guidelines to create earlier and broader patient access to biosimilars. Check out some initiatives from HTA bodies here:
HAS FR: https://t.co/xeOzzsrgF7
NICE UK https://t.co/kShNvVUO8a #ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud #ISPORBiosimilars other examples on page 18 of report here: KPMG (2019). Improving healthcare delivery in hospitals by optimized utilization of medicines.

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud One example: payers can create an environment that stimulates long-term competition eg. Adjusting the number of procurement winners according to the market characteristics #ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud Some examples are related to improving procurement practices to guarantee healthy and long term competition eg Adjusting the number of procurement winners according to the market characteristics; Guaranteeing that the procurement processes open after the entry of the first

[Catarina Lopes Pereira @Catarinaloperei]

@menzies_jeff @drddawoud @ISPORorg Agree, and in countries with socioeconomic constraints, biosimilars are sometimes the first time that the patients have access to this treatment. #isporbiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud One important aspect is the revision of treatment guidelines after the entry of a biosimilar...this could enable a earlier and broader access to biosimilars, see some examples for UK here https://t.co/f3MVNsfztv
https://t.co/oFYyVKQsgn
#ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud Depends on the challenging, on long term competition and procurement practices, check out some key principles below! #ISPORBiosimilars

[Catarina Lopes Pereira @Catarinaloperei]

@drddawoud There are many challenges from education of patients, HCP and healthcare community, to create an environment that stimulates long term competition eg. establishing sustainable and appropriate procurement mechanisms #ISPORBiosimilars

[ISPOR @ISPORorg]

Ahead of Thursday's #ISPORBiosimilars Twitter Chat, check out the recent #biosimilars webinar! https://t.co/P5dyXT3zMY

[Catarina Lopes Pereira @Catarinaloperei]

Check out the secret to improve access to value added medicines here:
https://t.co/EoyA8D80TI

[Medicines for Europe @medicinesforEU]

.@IQVIA_global report calls for better environment to improve #patient access to value added medicines #Valueaddedmeds, launched today in the @Europarl_EN in an event hosted by @LieveWierinck @ALDEgroup https://t.co/KvbRF714n2